Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Multiple Oral Doses of 2000 mg of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity in Subjects With Hypercholesterolemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 19 Apr 2010 New trial record